Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | IDE | P14735 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.31 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28794955 | 0.91 | TAAR1 (0.44) | TAAR1GBA1GAASPHK2SPHK1 | |
| SCHEMBL6484393 | 0.88 | GBA1 (0.44) | TAAR1GBA1GAAGNAI3GNAO1 | |
| SCHEMBL9261256 | 0.87 | GBA1 (0.43) | TAAR1GBA1GAAGNAI3GNAO1 | |
| SCHEMBL6760989 | 0.86 | TAAR1 (0.33) | TAAR1GBA1GAA | |
| SCHEMBL3834096 | 0.86 | TDP1 (0.35) | TAAR1GBA1GAATDP1L3MBTL1 | |
| SCHEMBL6648360 | 0.86 | TAAR1 (0.33) | TAAR1GBA1GAA | |
| SCHEMBL31397702 | 0.85 | TAAR1 (0.45) | TAAR1GBA1GAATDP1L3MBTL1 | |
| SCHEMBL3110597 | 0.84 | TAAR1 (0.43) | TAAR1GBA1TDP1L3MBTL1MITF | |
| SCHEMBL7023461 | 0.82 | TAAR1 (0.48) | TAAR1GBA1TDP1L3MBTL1MITF | |
| Hydrochloric Acid SCHEMBL28058916 | 0.82 | TAAR1 (0.42) | TAAR1TDP1L3MBTL1MITFAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133094-A1 | CURING AGENT FOR USE IN PRODUCTION OF POLYUREA RESIN, AND POLYUREA RESIN PRODUCTION METHOD USING SAME | Tosoh Corporation (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | TAAR1 4581/4885GBA1 1705/4885GAA 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.